Executive Summary
What this business is
Customers
UK adults and children facing multi-year public NHS ADHD waitlists—accessed either free via England's NHS Right to Choose GP referrals or via private self-pay.
Offering
CQC-regulated, consultant-psychiatrist-led ADHD and autism assessment, diagnosis, medication titration, and prescribing service for adults and under-18s, backed by a free online screener and companion app course.
Business model
Institutional healthcare-provider scaling powered by NHS Right to Choose public reimbursement contracts, GP patient-directed referrals, and private-pay clinics.
Pricing
Self-pay rates are £399 for diagnostic assessment, £599 for 12-week medication titration, and £230 for the app course; England patients qualify free under NHS Right to Choose (per-case NHS tariff undisclosed).
- Takeoff mode
- NHS Policy Referral Spillover
Post-2023 UK ADHD demand overwhelmed legacy providers like Psychiatry-UK with massive backlogs. Former NHS director Mark Pattison left the NHS mid-2024 to build a CQC-regulated alternative promising dramatically shorter wait times—leveraging England's 'Right to Choose' rule that lets patients instruct their GP to refer them to accredited private providers at NHS expense.
Although formal financials aren't published, combining £399 assessments + £599 titrations with 'thousands of patients in Year 1' and an 8,000/month assessment target implies tens of millions GBP in annualized potential (inferred), supporting 227 employees. However, checkout visits halving from 29.5K/mo (Apr–Jun) to 14.7K (Jul) reveals sharp pressure on self-pay momentum.
Operated by London-based Centre for ADHD Research & Excellence Ltd (Co. 14535089, incorporated ~Dec 2022) and led by founder Mark Pattison (ex-NHS director) with Deputy CEO & Co-founder Bobby Pratap. Noticeably, careadhd.co.uk now redirects to noodlehealth.com, branded as 'Noodle, formerly Care ADHD'.